# Afrezza® INHALE-1 Study in Pediatrics

Study · id `cardio:ct-nct04974528` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04974528](<https://clinicaltrials.gov/study/NCT04974528>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04974528

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.

## Technical summary

Registry record NCT04974528. Randomized; no masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2024-10-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 319 participants (enrolled count; ClinicalTrials.gov record NCT04974528, source copy `cardio:ctgov-nct04974528-2025-05-06`, retrieved 2026-10-26)
- Started: 2021-09-29 (actual) (ClinicalTrials.gov record NCT04974528, source copy `cardio:ctgov-nct04974528-2025-05-06`, retrieved 2026-10-26)
- Primary completion: 2024-10-03 (actual) (ClinicalTrials.gov record NCT04974528, source copy `cardio:ctgov-nct04974528-2025-05-06`, retrieved 2026-10-26)
- Completion: 2025-04-29 (actual) (ClinicalTrials.gov record NCT04974528, source copy `cardio:ctgov-nct04974528-2025-05-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04974528, source copy `cardio:ctgov-nct04974528-2025-05-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04974528-2025-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Afrezza® INHALE-1 Study in Pediatrics
- Acronym: INHALE-1
- Condition: Diabetes Mellitus, Type 1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Biological): Afrezza
- Intervention (Biological): Rapid-acting Insulin Analog
- Intervention (Biological): Basal Insulin
- Lead sponsor: Mannkind Corporation
- Lead sponsor class: INDUSTRY
- Collaborator: Jaeb Center for Health Research
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Mannkind Corporation (`cardio:org-mannkind-corporation`)
- Registry lists this organization as a collaborator: Jaeb Center for Health Research (`cardio:org-jaeb-center-for-health-research`)

## Provenance

Content hash: d6304d2a6299861afba4f201da43ebe0c021ce32d94b76de82d95ab887364b96
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
